Global Irritable Bowel Syndrome (IBS) Market Research Report 2026 Top companies are Allergan Plc, Sucampo Pharmaceuticals, Ironwood Pharmaceuticals, Inc., Astellas Pharma Inc., Valeant Pharmaceuticals, Abbott Laboratories, Synergy Pharmaceuticals, Inc
The Irritable Bowel Syndrome (IBS) report includes value chain examination for every one of the item sections. Value chain examination offers inside and out data about value expansion at each stage. The investigation incorporates drivers and restrictions for Pharmaceutical Market. The investigation likewise gives key market pointers influencing the development of the market. This Irritable Bowel Syndrome (IBS) Research report enables client to settle on exact choice so as to grow their market nearness, understanding of market patterns, openings and at last builds the clear insight of overall business.
Global Irritable Bowel Syndrome Market is expected to rise gradually to an estimated value of USD 7.82 billion by 2026, registering a CAGR of 12.45% in the forecast period of 2019-2026 with the annual sales of USD 3.06 billion in the year of 2018. This rise in market value can be attributed to the increasing awareness and concerns regarding the health of patients.
Download Free PDF Sample Copy of Report@ https://databridgemarketresearch.com/request-a-sample/?dbmr=global-irritable-bowel-syndrome-ibs-market
Global Irritable Bowel Syndrome (IBS) Market By Drug Type (Lubiprostone, Linaclotide, Eluxadoline, Rifaximin, Alosetron, and others), Medical Condition (IBS-constipation and IBS-diarrhea, mixed), Distribution Channel (Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies), End-Users (Hospitals, Clinics, Homecare settings), and Geography (North America, South America, Europe, Asia-Pacific, Middle East and Africa) – Industry Trends & Forecast to 2026
Key Market Competitors:
Few of the major competitors currently working in the irritable bowel syndrome market are Allergan Plc (Ireland), Sucampo Pharmaceuticals (U.S.), Ironwood Pharmaceuticals, Inc. (U.S.), Astellas Pharma Inc. (Japan), Valeant Pharmaceuticals (Canada), Abbott Laboratories (U.S.), Synergy Pharmaceuticals, Inc. (U.S.), Ardelyx, Inc. (U.S.), Nestle (Switzerland), Sebela Pharmaceuticals (Ireland), Probi (Sweden), Alfasigma USA, Inc. (Italy), RedHill Biopharma Ltd. (Israel), AstraZeneca (U.K), Ipsen (France), Novartis AG (Switzerland), Takeda Pharmaceutical Company Ltd (Japan), Synthetic Biologics, Inc. (U.S.), Protagonist Therapeutics Inc. (U.S.), Pfizer Inc (U.S.), Lexicon Pharmaceuticals, Inc. (U.S.), Innovate Biopharmaceuticals (U.S.) and few among others.
Global irritable bowel syndrome market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of irritable bowel syndrome market for global, Europe, North America, Asia-Pacific, South America and Middle East & Africa.
Irritable bowel syndrome is a division of Telehealth market. Telemental health, the use of telemedicine technology which provides mental health services from a distance. Additionally, it also provides consultation, supervision, health intervention, assessment, education, and information across distances.
According to CDC, there were approximately 3 million people in US being diagnosed by IBD in 2015. Another report by International Foundation of Gastrointestinal Disorders, mental disorders, suggests that worldwide prevalence rates were 10–15% in 2016. Same report says that there were around 2.4-3.5 million annual physician visits for IBD in the US alone. Almost more than half of these cases could have been avoided with the availability of proper medical treatment. This significant number is expected to act as a driver to the market
• Change in lifestyle and eating habits of population is responsible for the increase in incidence and prevalence rates which can drive the growth of the market.
• Wide no. of pipeline molecules and product launches will drive the growth of market.
• Rise in awareness about available treatment will drive the growth of market.
• Lack of straightforward treatment will restrain the market.
• Increase in the no. of generic competitors will hamper the market growth.
• Fewer Government initiatives taken in this direction.
Table Of Content: Irritable Bowel Syndrome (IBS) Market
Part 01: Executive Summary
Part 02: Scope Of The Report
Part 03: Irritable Bowel Syndrome (IBS)
Part 04: Global Irritable Bowel Syndrome (IBS) Market Sizing
Part 05: Global Irritable Bowel Syndrome (IBS) Market Segmentation By Product
Part 06: Five Forces Analysis
Part 07: Customer Landscape
Part 08: Geographic Landscape
Part 09: Decision Framework
Part 10: Drivers And Challenges
Part 11: Market Trends
Part 12: Vendor Landscape
Part 13: Vendor Analysis
For Detailed TOC @ https://databridgemarketresearch.com/toc/?dbmr=global-irritable-bowel-syndrome-ibs-market
Segmentation: Global Irritable Bowel Syndrome Market
By Drug Type
By Medical Condition
By Distribution Channel
• Hospital Pharmacies
• Online Pharmacies
• Retail Pharmacies
• Homecare settings
Key Developments in the Market:
• On 19th December 2017, Boehringer Ingelheim announced a collaborative agreement on the discovery and development of orally available novel Locked Nucleic Acid (LNA) oligonucleotides for the treatment of inflammatory bowel diseases (IBDs) with Roche. Together, Boehringer Ingelheim and Roche will leverage complementary expertise and innovative LNA technology to bring novel treatment approaches to IBD patients.
• On 14th February 2018, Regentys, a regenerative medicine company, announced its partnership with Cook Biotech Inc., to develop a novel treatment for ulcerative colitis. Under the terms, Cook Biotech will develop and manufacture Regentys’ licensed clinical product, ECMH™ Rectal Solution (Extracellular Matrix Hydrogel), which will be used in first-in-man clinical studies conducted by Regentys in 2018.
• In August 2016, Biosimilar product of Enbrel (etenercept), Elrezi (Novartis) got FDA approval for the treatment of inflammatory bowel disease. It will help growing the company and generate the revenue.
• In April 2016, the U.S. Food and Drug Administration (FDA) approved Inflectra (Celtrion, Inc.), a biosimilar to Remicade (Janssen Biotech, Inc.) for patients suffering from Crohn’s disease. This approval will provide patients some other alternatives and help in the growth of the Crohn’s disease market.
Inquire about this report from our expert’s @ https://databridgemarketresearch.com/inquire-before-buying/?dbmr=global-irritable-
Reasons to Purchase this Report
• Current and future of global irritable bowel syndrome market outlook in the developed and emerging markets
• The segment that is expected to dominate the market as well as the segment which holds highest CAGR in the forecast period
• Regions/Countries that are expected to witness the fastest growth rates during the forecast period
• The latest developments, market shares, and strategies that are employed by the major market players
Customization of the Report:
• All segmentation provided above in this report is represented at country level
• All products covered in the market, product volume and average selling prices will be included as customizable options which may incur no or minimal additional cost (depends on customization)
About Data Bridge Market Research:
Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.
Data Bridge Market Research
This release was published on openPR.
Permanent link to this press release:
You can edit or delete your press release Global Irritable Bowel Syndrome (IBS) Market Research Report 2026 Top companies are Allergan Plc, Sucampo Pharmaceuticals, Ironwood Pharmaceuticals, Inc., Astellas Pharma Inc., Valeant Pharmaceuticals, Abbott Laboratories, Synergy Pharmaceuticals, Inc here
News-ID: 1743647 • Views: 738
More Releases from Data Bridge Market Research
Nanomedicine Market Analysis Report Promising Industry Bright Future A Report By …
To prosper in this competitive market place, businesses consider taking up innovative solutions and market research report is one of them. Analysis and estimations derived through the enormous information gathered in this Global Nanomedicine market analysis report are extremely necessary when it comes to dominating the market or creating a mark in the market as a new emergent. A lot of efforts have been put together and no stone is
Oxidative Stress Analysis Market Recent Trends, In-depth Analysis, Market Size R …
Global Oxidative Stress Analysis Market By Product (Consumables, Instruments, Services), Technology (Elisa, Flow Cytometry, Chromatography, Microscopy, High- Content Screening, Label- Free Detection), Test Type (Indirect Assays, Antioxidant Capacity Assays, Enzyme- Based Assays, Reactive Oxygen Species-Based Assays), End- User (Pharmaceutical and Biotechnology Companies, Academic Research Institutes, Clinical Laboratories, Contract Research Organizations), Disease (Cardiovascular Disease, Diabetes, Chronic Obstructive Pulmonary Disease, Cancer, Asthma), Geography (North America, Europe, Asia-Pacific, South America, Middle East and
Global Pharmaceutical Excipients Market 2020 Top Companies are shland, Inc., BAS …
Global Pharmaceutical Excipients Market is registering a substantial CAGR of 6.78% in the forecast period of 2019-2026. The report contains data from the base year of 2018 and the historic year of 2017. This rise in the market can be attributed to rising of prescribed drugs, generics markets and consumption of biopharmaceuticals. Few of the major market competitors currently working in the Global Pharmaceutical Excipients Market are Ashland. , Roquette
Global Calcium Channel Blocker Market Showing Tremendous Growth With Top Players …
A new market study is released on Calcium Channel Blocker Market with data Tables for historical and forecast years represented with Chats & Graphs spread through Pages with easy to understand detailed analysis. This Calcium Channel Blocker Market report is delivered as the most relevant, unique, fair, and creditable global market research report to valuable customers and clients depending upon their specific business needs. It facilitates in adjusting the production
More Releases for IBS
Global IBS-C Drugs Market Size, Status and Forecast 2022
This report studies the global IBS-C Drugs market, analyzes and researches the IBS-C Drugs development status and forecast in United States, EU, Japan, China, India and Southeast Asia. This report focuses on the top players in global market, like Catalent Pharmaceuticals Solutions Nestle Abbott Laboratories Synergy Pharmaceuticals Sucampo Pharmaceuticals Novartis Pharma Ag Astellas Pharmaceuticals Ardelyx, Inc Synthetic Biologics, Inc Teva Pharmaceutical Industries Bama-Geve, SLU Ferring BV Ironwood Pharmaceuticals, Inc Salix Pharmaceuticals Ltd Norgine B.V Sample of this report is available upon request @ https://www.qyresearchreports.com/sample/sample.php?rep_id=1336446&type=E Table of Contents Global
IBS' solution to power China’s first Cruise Line
Trivandrum, 16 January 2013: Henna, the largest cruise ship in mainland China will run on IBS’ inventory and pricing management solution, Cruise Partner, when it makes its maiden journey on January 26, 2013. China based HNA Tourism Cruise and Yacht Management Company unveiled this cruise ship on November 28, 2012. Henna has 739 rooms for 1,965 passengers, as well as a complete range of facilities for living and entertainment. HNA
IBS Scherer presents three product videos on the internet
Action: Who wants to know how industrial parts cleaning is simply working, can get an idea now with just one mouse click on www.ibs-scherer.com. IBS Scherer GmbH, leading manufacturer of environmental-friendly complete solutions for cleaning small parts which are soiled with oil and grease, from Gau-Bickelheim – Germany, informs with three about two-minute product videos, how industrial parts cleaning works with IBS Parts Cleaning Devices. One mouse click and interested visitors
Cathay Pacific selects IBS Solution to help manage staff travel
Cathay Pacific has signed a multi-million dollar contract to implement IBS’ new generation solution, iFly Staff, to automate and improve the management of employee travel. iFly Staff will also be used for Cathay Pacific subsidiaries including sister airline Dragonair. The implementation of iFly Staff will result in an automated staff travel solution that supports the eligibility and entitlements offered to the airline’s employees and their dependants.
HaCon and IBS combine expertise in railway operation
Hanover (2010-07-06). Two Hanoverian companies now combine their expertise in questions of railway operations: With effect from 1 July 2010, the HaCon Ingenieurgesellschaft mbH, took over the engineering firm for railway operating systems (Ingenieurbüro für Bahnbetriebssysteme GmbH – IBS). This way HaCon expanded its services to include the areas operation simulation, vehicle and personnel planning and construction operations planning. This also includes consulting services concerning railway systems issues, such as travel
IBS’ iCargo gives Qantas a leading edge in Freight
~the solution will manage the international freight movements of the carrier ~ Trivandrum, India, 10 June 2010: Qantas, Australia’s national carrier and one of the world’s leading airlines, has implemented IBS’ Cargo Management Solution in its international air freight division, Qantas Freight. Through this deployment, the airline has successfully migrated its global cargo sales, reservations and capacity management functions to IBS’ iCargo platform. iCargo, a new generation end-to-end logistics solution, replaced